Innate aminoglycoside resistance of Achromobacter xylosoxidans is due to AxyXY-OprZ, an RND-type multidrug efflux pump

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 1, 2013, Pages 603-605

  Bador, Julien ^a   Amoureux, Lucie ^a   Blanc, Emmanuel ^a   Neuwirth, Catherine ^a  

^a DIJON UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; CARBAPENEM DERIVATIVE; CEFEPIME; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; DORIPENEM; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; KANAMYCIN; LEVOFLOXACIN; MEROPENEM; MOXIFLOXACIN; NALIDIXIC ACID; NETILMICIN; NORFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; TETRACYCLINE DERIVATIVE; TICARCILLIN; TIGECYCLINE; TOBRAMYCIN;

ACHROMOBACTER XYLOSOXIDANS; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; INFECTION RESISTANCE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; OPERON; PRIORITY JOURNAL; RESISTANCE NODULATION CELL DIVISION TYPE MULTIDRUG EFFLUX PUMP;

ACHROMOBACTER DENITRIFICANS; AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CARBAPENEMS; CYSTIC FIBROSIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FLUOROQUINOLONES; GENES, MDR; GENOME, BACTERIAL; GRAM-NEGATIVE BACTERIAL INFECTIONS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MEMBRANE TRANSPORT PROTEINS; MICROBIAL SENSITIVITY TESTS; RESPIRATORY TRACT INFECTIONS; SEQUENCE ANALYSIS, DNA;

EID: 84872018509     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01243-12     Document Type: Article

References (19)

1. Aisenberg G, Rolston KV, Safdar A. 2004. Bacteremia caused by Achromobacter and Alcaligenes species in 46 patients with cancer (1989-2003). Cancer 101:2134-2140.
2. Tena D, Gonzalez-Praetorius A, Perez-Balsalobre M, Sancho O, Bisquert J. 2008. Urinary tract infection due to Achromobacter xylosoxidans: report of 9 cases. Scand. J. Infect. Dis. 40:84-87.
3. De Baets F, Schelstraete P, Van Daele S, Haerynck F, Vaneechoutte M. 2007. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance. J. Cyst. Fibros. 6:75-78.
4. Razvi S, Quittell L, Sewall A, Quinton H, Marshall B, Saiman L. 2009. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005. Chest 136:1554-1560.
5. Ridderberg W, Bendstrup KE, Olesen HV, Jensen-Fangel S, Norskov-Lauritsen N. 2011. Marked increase in incidence of Achromobacter xylosoxidans infections caused by sporadic acquisition from the environment. J. Cyst. Fibros. 10:466-469.
6. Hansen CR, Pressler T, Nielsen KG, Jensen PO, Bjarnsholt T, Hoiby N. 2010. Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients. J. Cyst. Fibros. 9:51-58.
7. Mantovani RP, Levy CE, Yano T. 2012. A heat-stable cytotoxic factor produced by Achromobacter xylosoxidans isolated from Brazilian patients with CF is associated with in vitro increased proinflammatory cytokines. J. Cyst. Fibros. 11:305-311.
8. Almuzara M, Limansky A, Ballerini V, Galanternik L, Famiglietti A, Vay C. 2010. In vitro susceptibility of Achromobacter spp. isolates: comparison of disk diffusion, Etest and agar dilution methods. Int. J. Antimicrob. Agents 35:68-71.
9. Glupczynski Y, Hansen W, Freney J, Yourassowsky E. 1988. In vitro susceptibility of Alcaligenes denitrificans subsp. xylosoxidans to 24 antimicrobial agents. Antimicrob. Agents Chemother. 32:276-278.
10. Saiman L, Chen Y, Tabibi S, San Gabriel P, Zhou J, Liu Z, Lai L, Whittier S. 2001. Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. J. Clin. Microbiol. 39:3942-3945.
11. Bador J, Amoureux L, Duez JM, Drabowicz A, Siebor E, Llanes C, Neuwirth C. 2011. First description of an RND-type multidrug efflux pump in Achromobacter xylosoxidans, AxyABM. Antimicrob. Agents Chemother. 55:4912-4914.
12. Aires JR, Kohler T, Nikaido H, Plesiat P. 1999. Involvement of an active efflux system in the natural resistance of Pseudomonas aeruginosa to aminoglycosides. Antimicrob. Agents Chemother. 43:2624-2628.
13. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T. 2000. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 44:3322-3327.
14. Mine T, Morita Y, Kataoka A, Mizushima T, Tsuchiya T. 1999. Expression in Escherichia coli of a new multidrug efflux pump, MexXY, from Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 43:415-417.
15. Muller C, Plesiat P, Jeannot K. 2011. A two-component regulatory system interconnects resistance to polymyxins, aminoglycosides, fluoroquinolones, and beta-lactams in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 55:1211-1221.
16. Matsuo Y, Eda S, Gotoh N, Yoshihara E, Nakae T. 2004. MexZ-mediated regulation of mexXY multidrug efflux pump expression in Pseudomonas aeruginosa by binding on the mexZ-mexX intergenic DNA. FEMS Microbiol. Lett. 238:23-28.
17. Mao W, Warren MS, Black DS, Satou T, Murata T, Nishino T, Gotoh N, Lomovskaya O. 2002. On the mechanism of substrate specificity by resistance nodulation division (RND)-type multidrug resistance pumps: the large periplasmic loops of MexD from Pseudomonas aeruginosa are involved in substrate recognition. Mol. Microbiol. 46:889-901.
18. Morita Y, Tomida J, Kawamura Y. 2012. Primary mechanisms mediating aminoglycoside resistance in the multidrug-resistant Pseudomonas aeruginosa clinical isolate PA7. Microbiology 158:1071-1083.
19. Moore RA, DeShazer D, Reckseidler S, Weissman A, Woods DE. 1999. Efflux-mediated aminoglycoside and macrolide resistance in Burkholderia pseudomallei. Antimicrob. Agents Chemother. 43:465-470.